Atrium Therapeutics, Inc. balance sheet RNA

As of Jun 30, 2026, Atrium Therapeutics, Inc. had total assets of $280.5 million and total liabilities of $65.9 million. Stockholders' equity was $214.6 million. It held $263.9 million in cash and investments against $1.7 million of total debt, net cash of $262.2 million. The current ratio, current assets divided by current liabilities, was 8.73.

USD in millions, except ratios and per-share amounts. The percent under a figure is the change from the year before.

Line
FY 2026
Jun 30, 2026
Assets
Cash
72
Short-term investments
192
Cash and investments
264
Total current assets
275
Property and equipment, net
4
Total assets
281
Liabilities and equity
Accounts payable
4
Total current liabilities
32
Total liabilities
66
Stockholders' equity
215
Debt
Lease liabilities
2
Total debt
2
Net cash
262
Ratios
Current ratio
8.73x
Debt to equity
0.01x
Book value per share
12.54
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except ratios and per-share amounts. Cash and investments adds short-term and long-term marketable securities to cash. Debt due within a year is the borrowings that are not already in long-term debt. Total debt is those borrowings plus lease liabilities. Net cash is cash and investments minus total debt. Return on equity and return on assets divide the trailing twelve months of net income by the balance on that date. Debt to EBITDA uses the trailing twelve months of EBITDA. The first column is the latest balance sheet when it is newer than the latest fiscal year. More on our methodology.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
RNA (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
San Diego, CA
SEC filer status
, Emerging growth company
SEC CIK
2093101

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.